ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
7.32
+0.07 (0.97%)
At close: Aug 6, 2026, 4:00 PM EDT
7.33
+0.01 (0.14%)
After-hours: Aug 6, 2026, 7:59 PM EDT
ImmunityBio Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -992.42 | -351.47 | -413.65 | -583.85 | -417.32 | -349.85 |
Depreciation & Amortization | 16.6 | 15.53 | 17.55 | 18.51 | 18.26 | 14.24 |
Stock-Based Compensation | 34.31 | 36.81 | 34.43 | 49.16 | 40.18 | 57.18 |
Other Adjustments | 674 | 48.53 | -10.16 | 145.59 | 29.37 | 23.12 |
Change in Receivables | -31.35 | -40.21 | -2.36 | - | - | - |
Changes in Inventories | -11.93 | -6.33 | -8.27 | - | - | - |
Changes in Accounts Payable | 3.24 | -0.19 | -3.17 | -6.48 | 8 | -3.72 |
Changes in Accrued Expenses | 19.09 | 3.18 | -1.51 | 6.69 | 4.1 | 5.18 |
Changes in Other Operating Activities | -8.73 | -10.79 | -4.12 | 3.62 | -20.1 | -20.58 |
Operating Cash Flow | -281.14 | -304.94 | -391.24 | -366.76 | -337.51 | -274.42 |
Operating Cash Flow Growth | - | - | - | - | - | - |
Capital Expenditures | -6.94 | -3.85 | -6.89 | -30.58 | -78.16 | -33.56 |
Sale of Property, Plant & Equipment | - | - | - | - | - | 20.5 |
Purchases of Intangible Assets | -0.44 | -0.41 | - | - | -21.23 | - |
Purchases of Investments | -539.52 | -241.37 | -140.22 | -10.36 | -35.31 | -141.75 |
Proceeds from Sale of Investments | 269.99 | 95.82 | 136.61 | 10.47 | 162 | 69.93 |
Cash Acquisitions | - | - | -1 | - | - | - |
Other Investing Activities | - | - | -0.75 | - | - | - |
Investing Cash Flow | -276.91 | -149.8 | -12.25 | -30.47 | 27.3 | -84.89 |
Short-Term Debt Issued | 2.95 | 2.88 | - | - | - | - |
Net Short-Term Debt Issued (Repaid) | 2.95 | 2.88 | - | - | - | - |
Long-Term Debt Issued | 74.95 | - | 96.96 | 451.46 | 174.13 | 338.5 |
Net Long-Term Debt Issued (Repaid) | 74.95 | - | 96.96 | 451.46 | 174.13 | 338.5 |
Issuance of Common Stock | 429.88 | 400.78 | 190.2 | 110.4 | 60.5 | 169.99 |
Repurchase of Common Stock | -8.05 | -2.27 | -5.47 | -3.44 | -0.62 | -4.06 |
Net Common Stock Issued (Repurchased) | 421.83 | 398.52 | 184.74 | 106.95 | 59.89 | 165.93 |
Other Financing Activities | -2.94 | -1.16 | -0.06 | -0.08 | -0.4 | 1.02 |
Financing Cash Flow | 496.78 | 400.24 | 281.63 | 558.34 | 233.61 | 505.44 |
Foreign Exchange Rate Adjustments | 0.07 | 0.02 | -0.02 | -0.29 | 0.28 | 0.05 |
Net Cash Flow | -61.2 | -54.48 | -121.88 | 160.82 | -76.32 | 146.19 |
Free Cash Flow | -288.07 | -308.78 | -398.12 | -397.34 | -415.67 | -307.98 |
Free Cash Flow Growth | - | - | - | - | - | - |
FCF Margin | -173.76% | -272.56% | -2700.06% | -63881.20% | -173196.00% | -32974.50% |
Free Cash Flow Per Share | -0.29 | -0.34 | -0.57 | -0.78 | -1.04 | -0.79 |
Levered Free Cash Flow | -903.12 | -350.95 | -323 | -139.98 | -310.35 | -46.73 |
Unlevered Free Cash Flow | -240.41 | -258.37 | -350.58 | -370.47 | -419.23 | -368.73 |